Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer
详细信息 查看全文
- 作者：William Cruz-Mu?oz (1)
Teresa Di Desidero (1)
Shan Man (1)
Ping Xu (1)
Maria Luz Jaramillo (2)
Kae Hashimoto (1)
Catherine Collins (2)
Myriam Banville (2)
Maureen D. O’Connor-McCourt (2)
Robert S. Kerbel (1) (3) - 关键词：Metastasis ; Ovarian cancer ; Chemotherapy ; Topotecan ; Pazopanib ; Resistance
- 刊名：Angiogenesis
- 出版年：2014
- 出版时间：July 2014
- 年：2014
- 卷：17
- 期：3
- 页码：661-673
- 全文大小：
- 参考文献：1. Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4(6):423-36 CrossRef
2. Pasquier E, Kavallaris M, Andre N (2010) Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 7(8):455-65 CrossRef
3. Rapisarda A et al (2004) Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 64(19):6845-848 CrossRef
4. Lee K et al (2009) Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci USA 106(7):2353-358 CrossRef
5. Folkins C et al (2009) Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res 69(18):7243-251 CrossRef
6. Martin-Padura I et al (2012) Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. Lab Invest 92(7):952-66 CrossRef
7. Browder T et al (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60(7):1878-886
8. Klement G et al (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105(8):R15–R24 CrossRef
9. Daenen LG et al (2009) Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models. Mol Cancer Ther 8(10):2872-881 CrossRef
10. Shaked Y et al (2005) Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 106(9):3058-061 CrossRef
11. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3(10):721-32 CrossRef
12. Munoz R et al (2006) Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 66(7):3386-391 CrossRef
13. Hashimoto K et al (2010) Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther 9(4):996-006 CrossRef
14. Merritt WM et al (2009) Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther 8(16):1596-603 CrossRef
15. Emmenegger U et al (2011) Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia 13(1):40-8
16. Kerbel RS (2012) Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer. J Mammary Gland Biol Neoplasia 17(3-):229-39 CrossRef
17. Bocci G et al (2008) Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer 98(10):1619-629 CrossRef
18. Shen J et al (2009) Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid. Cancer Res 69(14):5885-892 CrossRef
19. Hubbard KE et al (2009) Application of a highly specific and sensitive fluorescent HPLC method for topotecan lactone in whole blood. Biomed Chromatogr 23(7):707-13 CrossRef
20. Folkins C et al (2007) Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 67(8):3560-564 CrossRef
21. Mizuno H, Kitada K, Nakai K, Sarai A (2009) PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics 2:18 CrossRef
22. McFadyen MC et al (2001) Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br J Cancer 85(2):242-46 CrossRef
23. Garcia AA et al (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26(1):76-2 CrossRef
24. Dellapasqua S et al (2008) Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26(30):4899-905 CrossRef
25. Bottini A et al (2006) Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 24(22):3623-628 CrossRef
26. Koopman M et al (2013) Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): the phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 31:Abstr 3502
27. Miklos GL (2012) Bevacizumab in neoadjuvant treatment for breast cancer. N Engl J Med 366(17):1638 (author reply 1639-0)
28. Montero AJ, Vogel C (2012) Fighting fire with fire: rekindling the bevacizumab debate. N Engl J Med 366(4):374-75 CrossRef
29. Dawood S et al (2012) The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy. Cancer 118(11):2780-786 CrossRef
30. Aogi K et al (2011) First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study. Breast Cancer Res Treat 129(3):829-38 CrossRef
31. Thomssen C et al (2012) First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study. Oncology 82(4):218-27 CrossRef
32. Smith I et al (2011) Final overall survival results and effect of prolonged (??year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial. Breast Cancer Res Treat 130(1):133-43 CrossRef
33. Barrios CH et al (2010) Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 121(1):121-31 CrossRef
34. Bergh J, Greil R, Voytko N (2011) Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). J Clin Oncol 28:LBA 1010
35. Merritt WM et al (2010) Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther 9(4):985-95 CrossRef
36. Kumar S et al (2011) Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin Cancer Res 17(17):5656-667 CrossRef
37. Hackl C et al (2013) Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut 62(2):259-71
38. Goh F, Sambanis A (2011) In vivo noninvasive monitoring of dissolved oxygen concentration within an implanted tissue-engineered pancreatic construct. Tissue Eng Part C Methods 17(9):887-94 CrossRef
39. Kato H et al (2004) A randomized trial of adjuvant chemotherapy with Uracil–Tegafur for adenocarcinoma of the lung. New Engl J Med 350:1713-721 CrossRef
40. Garcia et al (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and princess Margaret hospital phase II consortia. J Clin Oncol 26:76-2 CrossRef
41. Dellapasqua et al (2008) Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26:4899-905 CrossRef
42. Berendsen HH et al (1988) Characterization of three small cell lung cancer cell lines established from one patient during longitudinal follow-up. Cancer Res 48:6891-899
43. Kuczynski et al (2013) Drug rechallenge and treatment beyond progression in oncology: examples, mechanisms and implications of reversible drug resistance. Nature Rev Clin Oncol 10:571-87 CrossRef
44. Rochat B et al (2001) Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther 296(2):537-41
45. Wittig R et al (2002) Candidate genes for cross-resistance against DNA-damaging drugs. Cancer Res 62(22):6698-705
46. Oshita SE et al (2010) The small heat shock protein HspB2 is a novel anti-apoptotic protein that inhibits apical caspase activation in the extrinsic apoptotic pathway. Breast Cancer Res Treat 124(2):307-15 CrossRef
47. Langbein S et al (2006) Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer 94(4):578-85 CrossRef - 作者单位：William Cruz-Mu?oz (1)
Teresa Di Desidero (1)
Shan Man (1)
Ping Xu (1)
Maria Luz Jaramillo (2)
Kae Hashimoto (1)
Catherine Collins (2)
Myriam Banville (2)
Maureen D. O’Connor-McCourt (2)
Robert S. Kerbel (1) (3)
1. Biological Sciences Platform, S-217, Sunnybrook Research Institute, 2075 Bayview Ave., Toronto, ON, M4N 3M5, Canada
2. National Research Council of Canada, Human Health Therapeutics, NRCC, Montreal, QC, Canada
3. Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada - ISSN：1573-7209
文摘
An alternative or follow-up adjunct to conventional maximum tolerated dose (MTD) chemotherapy now in advanced phase III clinical trial assessment is metronomic chemotherapy—the close regular administration of low doses of drug with no prolonged breaks. A number of preclinical studies have shown metronomic chemotherapy can cause long term survival of mice with advanced cancer, including metastatic disease, in the absence of overt toxicity, especially when combined with targeted antiangiogenic drugs. However, similar to MTD chemotherapy acquired resistance eventually develops, the basis of which is unknown. Using a preclinical model of advanced human ovarian (SKOV-3-13) cancer in SCID mice, we show that acquired resistance can develop after terminating prolonged (over 3?months) successful therapy utilizing daily oral metronomic topotecan plus pazopanib, an oral antiangiogenic tyrosine kinase inhibitor (TKI). Two resistant sublines were isolated from a single mouse, one from a solid tumor (called KH092-7SD, referred to as 7SD) and another from ascites tumor cells (called KH092-7AS, referred to as 7AS). Using these sublines we show acquired resistance to the combination treatment is due to tumor cell alterations that confer relative refractoriness to topotecan. The resistant phenotype is heritable, associated with reduced cellular uptake of topotecan and could not be reversed by switching to MTD topotecan or to another topoisomerase-1 inhibitor, CPT-11, given either in a metronomic or MTD manner nor switching to another antiangiogenic drug, e.g. the anti-VEGFR-2 antibody, DC101, or another TKI, sunitinib. Thus, in this case cross resistance seems to exist between MTD and metronomic topotecan, the basis of which is unknown. However, gene expression profiling revealed several potential genes that are stably upregulated in the resistant lines, that previously have been implicated in resistance to various chemotherapy drugs, and which, therefore, may contribute to the drug resistant phenotype.